Kalaris Therapeutics, Inc.
Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for prevalent retinal diseases. Its lead product candidate, TH103, is an intravitreally administered, fully humanized recombinant anti-VEGF fusion protein designed for extended retention in the eye and enhanced VEGF inhibition. Kalaris is evaluating TH103 in a Phase 1b/2 dose-finding study for neovascular age-related macular degeneration (nAMD), and is considering its development for other VEGF-mediated retinal diseases, including diabetic eye disease and retinal vein occlusion. Kalaris retains worldwide development and commercialization rights to TH103. If approved, it intends to commercialize the product with its own specialty salesforce. The company also plans to strengthen its pipeline through internal discovery and development, licensing, collaborations or acquisitions.
No SEC Form 4 filings for $KLRS in the last 30 days.
See all $KLRS insider activity →Kalaris Therapeutics, Inc. (KLRS) reported Q3 GAAP EPS of -$0.46, beating estimates by $0.05. The company had $82.9M in cash, cash equivalents, and marketable securities as of September 30, 2026, according to a press release.
Kalaris reported a Q3 2026 net loss of $11.0 million, down from $11.9 million a year earlier. The company had $82.9 million in cash as of September 30, expecting it to last into 2028. Phase 1b/2 TH103 study results are now expected in the second half of 2027 due to a supply issue. R&D expenses were $8.3 million, down from $9.1 million in Q3 2025.
Kalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update Preliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD is now expected in 2H 2027 Recently completed technology transfer from pilot to commercial-scale manufacturer with te
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning KLRS (Kalaris Therapeutics, Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 2 bearish.
Recent KLRS coverage spans earnings, technology and financial news.
The modest earnings beat may generate slight buying pressure.
The loss and reduced R&D spend may pressure the stock lower, though ample cash runway offers some support.
Earnings miss and delayed data likely weigh on the stock.
The 8-K provides fresh balance-sheet runway guidance and updated TH103 clinical execution milestones, which can shift near-term risk and valuation expectations.
The immediate move is tied to the CFO appointment, but the article provides no new financial guidance or clinical readout.
AlphAI scores every news story that mentions KLRS with an AI model for sentiment and relevance, and aggregates insider trades from Kalaris Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kalaris Therapeutics, Inc. (KLRS) reported Q3 GAAP EPS of -$0.46, beating estimates by $0.05. The company had $82.9M in cash, cash equivalents, and marketable securities as of September 30, 2026, according to a press release.
Kalaris reported a Q3 2026 net loss of $11.0 million, down from $11.9 million a year earlier. The company had $82.9 million in cash as of September 30, expecting it to last into 2028. Phase 1b/2 TH103 study results are now expected in the second half of 2027 due to a supply issue. R&D expenses were $8.3 million, down from $9.1 million in Q3 2025.
Kalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update Preliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD is now expected in 2H 2027 Recently completed technology transfer from pilot to commercial-scale manufacturer with te
Kalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $
Kalaris Therapeutics (NASDAQ:KLRS) shares fell 6.4% on Monday after the company named Liisa Bayko as its new CFO. Bayko has over 20 years in biotech finance, most recently at Evercore ISI. Kalaris said it continues enrolling a Phase 1b/2 study of TH103 for treatment-naïve neovascular age-related macular degeneration.
Kalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d125092dex101.htm EX-10.1 EX-10.1 EXHIBIT 10.1 Execution Version EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of July 7, 2026 by and between Kalaris Therapeutics, Inc. (the “Company”), and Liisa Bayko (the “Executive”) (together, the “Part
Kalaris Therapeutics (NASDAQ:KLRS) said expanded Phase 1a data for TH103 in neovascular age-related macular degeneration showed vision and retinal-anatomy improvements, with intraocular retention suggested by plasma pharmacokinetics. The company reported 41% of treatment-naive patients delaying retreatment beyond four months after one injection, and no intraocular inflammation at 2.5 mg. KLRS rose about 18% to $5.43.
Kalaris Therapeutics (NASDAQ:KLRS) shares rose about 29% after Phase 1a results for TH103 in neovascular age-related macular degeneration. The company reported vision and retinal anatomy improvements in expanded cohorts of 20 patients, with no intraocular inflammation at 2.5 mg and one transient case at 5 mg. TH103 showed lower Cmax versus leading anti-VEGF agents and longer retreatment intervals. Phase 1b/2 enrollment is ongoing, with initial data expected in H1 2027.
Kalaris Therapeutics (KLRS) reported expanded Phase 1a data for TH103 in neovascular age-related macular degeneration. The study included 17 treatment-naive and 3 treatment-experienced patients with 6-month follow-up. Plasma Cmax was 27 to 53 times lower than leading anti-VEGF agents, with 29% needing no anti-VEGF during follow-up. Safety showed no IOI at 2.5 mg and one transient IOI at 5 mg.
Kalaris Therapeutics (Nasdaq: KLRS) said it appointed Laurie Keating to its Board of Directors effective Aug. 1, 2026, replacing Morana Jovan-Embiricos, who is stepping down. Keating is chair of PepGen (Nasdaq: PEPG) and a board member of Immuneering (Nasdaq: IMRX). Kalaris is developing TH103 for neovascular AMD.
